AWA
CRSP icon

Arkadios Wealth Advisors’s CRISPR Therapeutics CRSP Stock Holding History

Arkadios Wealth Advisors’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$9.51K Hold
200
– – ﹤0.01% 1683
2025
Q4 		$10.5K Hold
200
– – ﹤0.01% 1559
2025
Q3 		$13K Sell
200
-700
-78% -$40.2K ﹤0.01% 1462
2025
Q2 		$43.8K Buy
+900
New +$34.8K ﹤0.01% 1292

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GP
GSK plc London $599M AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Arkadios Wealth Advisors's CRSP Position: Q1 2026 in Review

Arkadios Wealth Advisors reduced its CRISPR Therapeutics (CRSP) stake by 0.01% in Q1 2026, selling an estimated $53 and leaving 9,416 shares worth $448K. The position accounts for 0.01% of the portfolio, ranked #1170.

Arkadios Wealth Advisors first reported a position in CRSP in Q1 2020 and has held it in 24 quarters since. The position peaked at $971K in Q4 2021. 488 funds tracked by Wall St. Rank hold CRSP as of Q1 2026.

  • Arkadios Wealth Advisors held 9,416 shares of CRISPR Therapeutics worth $448K as of Q1 2026.
  • Arkadios Wealth Advisors sold 1 CRISPR Therapeutics share in Q1 2026, an estimated $53.
  • CRISPR Therapeutics made up 0.01% of Arkadios Wealth Advisors's portfolio in Q1 2026, its #1170 holding.
  • Arkadios Wealth Advisors first reported a position in CRISPR Therapeutics in Q1 2020 and has held it in 24 quarters since.
  • Arkadios Wealth Advisors's CRISPR Therapeutics position peaked at $971K in Q4 2021.
  • 488 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q1 2026.

Based on Arkadios Wealth Advisors's 13F filing for Q1 2026, filed 18 May 2026.